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Summary We report a case of idiopathic dilated cardiomyopathy with severe heart failure
and complete left bundle branch block (CLBBB) which exhibited an excellent response to car-
diac resynchronization therapy (CRT). A 71-year-old male had been treated for 9 years with
medication for chronic heart failure. He was referred to hospital with a complaint of dyspnea.
An electrocardiogram showed CLBBB, with a QRS-width of 200ms. Markedly dilated left ven-
tricular (LV) chamber with a low ejection fraction (EF) of 18% and severe mitral regurgitation
were registered by echocardiogram. Myocardial neuronal 123I-metaiodobenzylguanidine uptake
was reduced, with a heart-to-mediastinum (H/M) ratio of 1.88. Immediately after the intro-guanidine;
Superresponder;
Carvedilol
duction of CRT, clinical improvement was observed. At 1-year follow-up, LV chamber size and
cardiac function were almost normalized, with an EF of 53%. Cardiac sympathetic nerve activity
(CSNA) was simultaneously normalized, with an H/M ratio of 2.32 and a washout rate of 14.7%.
However, after the cessation of carvedilol administration, CSNA and LV systolic function were
slightly aggravated, with an H/M ratio of 2.20, a washout rate of 15.9%, and an EF of 44%. In
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the present case, the excellent improvement in cardiac function and CSNA was caused by the
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H/M ratio was 2.20/2.38 (early phase/delayed phase), and
the washout rate was 15.9% (Table 2). Although he wascombined effects of beta-blo
© 2009 Japanese College of C
Introduction
Cardiac resynchronization therapy (CRT) for idiopathic
dilated cardiomyopathy (DCM) with severely impaired car-
diac function [New York Heart Association (NYHA) functional
class III/IV] and complete left bundle branch block (CLBBB)
is well established. However, approximately 30% of the
patients who fulﬁll the CRT selection criteria are regarded
as ‘‘nonresponders’’, who do not clinically beneﬁt after
CRT [1]. On the other hand, it has recently been reported
that some cases exhibit excellent responses to CRT [2—4].
In these cases, cardiac function was almost normalized by
CRT (EF > 50%) and they were called ‘‘superresponders’’ (or
‘‘hyperresponders’’). We assessed the cardiac sympathetic
nerve activity in the case of a ‘‘superresponder’’ to CRT,
who had been followed up over a long-term of 9 years.
Moreover, we considered whether it was valid to regard
‘‘superresponders’’ as having ‘‘dyssynchrony-induced car-
diomyopathy.’’
Case report
A 71-year-old male was ﬁrst informed that he had inter-
mittent left bundle branch block and left ventricular (LV)
dysfunction with dyssynchrony during a complete physi-
cal checkup at the age of 61, when he was asymptomatic
(Fig. 1). He had no habits of excessive alcohol drinking.
Moreover, he had no history of tachyarrhythmia. At the
age of 62, he was admitted to our hospital because of
exertional dyspnea. Coronary angiography showed normal
coronary arteries and left ventriculography revealed dif-
fusely severe hypokinesis of LV, with an ejection fraction (EF)
of 30%. He was then diagnosed with DCM. Conventional med-
ical treatment including beta-blocker (carvedilol), diuretic
(furosemide), and angiotensin-converting enzyme inhibitor
(ACEI) (enarapril) was initiated. Since he was 63 years’ old,
electrocardiograms (ECG) have consistently shown CLBBB.
The subjective symptoms were unchanged for 7 years, with
NYHA functional class II, although LV remodeling gradually
developed (Table 1). The serum brain natriuretic peptide
(BNP) concentration was getting higher during the clinical
course (Table 1). At the age of 70, despite medical treatment
with diuretics (azosemide and spironolactone), angiotensin
II receptor blocker (ARB) (candesartan), and beta-blocker
(carvedilol 10mg/day), he was suffering from progressive
dyspnea on exertion. Home oxygen therapy was introduced
by his personal doctor. As his symptoms took a turn for the
worse 2 weeks prior to referral, he was admitted to our hos-
pital. A chest radiograph showed pulmonary congestion and
marked cardiomegaly, with a cardio-thoracic ratio (CTR) of
63% (Fig. 2). An ECG showed CLBBB with a QRS-width of
200ms (Fig. 2). Laboratory data revealed moderate renal
dysfunction (urea nitrogen/creatinine of 34.9/1.70mg/dl)
and an extremely high level of BNP (1091.8 pg/ml).
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chocardiography revealed marked LV dilatation [dimen-
ion of LV end-diastole (Dd)/dimension of LV end-systole
Ds) of 78/72mm], wall thinning in the LV anteroseptal
rea and impaired LV contraction, with EF of 18% (Fig. 3).
yspnea was relieved with intensive diuresis and oxygen
upply. 123I-metaiodobenzylguanidine (MIBG) scintigraphy
as conducted to evaluate the degree of cardiac sympa-
hetic nervous system derangement, reﬂecting the severity
f myocardial damage in DCM. The heart-to-mediastinum
H/M) ratio (H/M) was moderately decreased in the early
hase, with a value of 1.88 (Table 2). Because of mechani-
al problems, no delayed planar MIBG image was acquired.
he patient was transferred to another hospital for the
mplantation of a CRT device with a deﬁbrillator (CRT-D)
Concerto C154DWK, Medtronic, Minneapolis, MN, USA). Pac-
ng leads were positioned in the right atrial appendage,
he right ventricular apex, and the lateral branch of the
oronary vein. The lower rate and the atrio-ventricular
elay were optimized at 50 bpm and 120ms, respectively.
mmediately after the initiation of CRT, clinical improve-
ent was observed. Medical therapy, including diuretics,
RB, and beta-blocker, was maintained after the CRT. One
ear later, CRT enabled the patient to walk up a steep
lope as long as 4 km without feeling shortness of breath.
t the 1-year follow-up, ECG showed a narrow QRS-width
f 110ms under biventricular pacing (Fig. 4). A chest
adiograph indicated a normal CTR of 47% (Fig. 4). Echocar-
iography revealed a normal LV chamber size (Dd/Ds of
2/38mm), mild concentric hypertrophy (‘‘elimination of
all thinning’’), and improved contractile function, with
n EF of 53% (Fig. 3). LV dyssynchrony was visually well-
orrected. No signiﬁcant mitral regurgitation was detected
y color Doppler imaging. The serum BNP concentration
as 13.7 pg/ml (normal range: <18.4 pg/ml). MIBG scintig-
aphy disclosed a normal pattern, with the H/M ratio of
.32/2.48 (early phase/delayed phase) and the washout
ate of 14.7%. After informed consent was obtained, beta-
locker (carvedilol 10mg/day) was discontinued. A thorough
linical follow-up was conducted every 2 weeks after that.
wo weeks later, the ECG was unchanged, except for a
light increase in the heart rate (89 bpm) and the QRS
idth (120ms) (Fig. 5). One month after the cessation of
arvedilol administration, echocardiography revealed mild
V dilatation and mild aggravation of LV contractile function
Dd/Ds of 56/43mm and EF of 44%). LV synchrony was visu-
lly maintained. CTR and BNP value slightly increased to
0% and 22.3 pg/ml, respectively. Moreover, MIBG scintig-
aphy disclosed slight aggravation of the parameters: theompletely free from palpitations and shortness of breath
uring the 1-month follow-up, beta-blocker therapy was
esumed. One month after the administration of carvedilol
10mg/day), the echocardiographic parameters returned to
aseline. Moreover, carvedilol was increased to the maxi-
e58 K. Ishibashi et al.
Figure 1 Electrocardiogram (ECG) and M-mode echocardiogram at the age of 62. The ECG showed both a wide QRS and a narrow
Q ge o
w ough
m B).
m
t
c
mRS, indicating intermittent left bundle branch block at the a
aves with slight ST depressions in the leads I, II, III, aVF, V4 thr
ovement in the left ventricle (LV) with poor LV performance (al dosage of 20mg/day. Under the CRT and the medical
reatment with diuretics, ARB, and beta-blocker, his clinical
ondition remained stable in the follow-up over the next 3
onths.
D
T
Ff 62 (A). In the narrow QRS pattern, ECG showed inverted T
V6 (A). The M-mode echocardiogram revealed an asynchronousiscussion
his case report indicates two major ﬁndings as follows.
irst, even if severe heart failure persists for a long time,
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Table 1 Time course of echocardiographic parameters, heart rate, blood pressure, CTR and BNP before cardiac resynchroniza-
tion therapy.
Age (years) 61 62 65 66 70
Dd (mm) 60 64 66 74 78
Ds (mm) 52 54 57 64 72
EF (%) 32 30 28 26 18
MR Mild Mild Mild Moderate Severe
HR (bpm) 70 85 75 88 85
BP (mmHg) 140/80 130/86 130/80 112/70 98/62
CTR (%) 52 50 51 55 63
BNP (pg/ml) — 78.9 103.9 347.4 1091.8
Dd, Dimension of left ventricular end-diastole; Ds, dimension of left ventricular end-systole; EF, ejection fraction; MR, mitral regurgita-
tion; HR, heart rate; BP, blood pressure; CTR, cardio-thoracic ratio; BNP, brain natriuretic peptide.
Figure 2 Chest radiograph and electrocardiogram on admission.
Figure 3 M-mode echocardiogram before and after cardiac resynchronization therapy (CRT). Dd, Dimension of left ventricular
end-diastole; Ds, dimension of left ventricular end-systole; EF, ejection fraction.
e60 K. Ishibashi et al.
Table 2 123I-metaiodobenzylguanidine scintigraphic parameters.
Pre-CRT Post-CRT beta-blocker (+) Post-CRT beta-blocker (−)
H/M ratio (early phase) 1.88 2.32 2.20
H/M ratio (delayed phase) — 2.48 2.38
Washout rate — 14.7 15.9
CRT, Cardiac resynchronization therapy; H/M ratio, heart-to-mediastinum ratio.
Figure 4 Chest radiograph and electrocardiogram after a year following cardiac resynchronization therapy.
Figure 5 Trend of electrocardiograms. CRT, cardiac resynchronization therapy.
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certain cases show excellent response to CRT. Second, our
case of ‘‘superresponder’’ to CRT is not equivalent to
dyssynchrony-induced cardiomyopathy from the viewpoint
of the response to the cessation of beta-blocker therapy.
Although CLBBB has been well known as an accelerat-
ing factor for heart failure, it is still controversial which
comes ﬁrst, electrical or mechanical failure [5]. According to
the Framingham study, 28% of asymptomatic patients devel-
oped heart failure after the appearance of CLBBB [6]. This
study suggests that certain CLBBB may mainly contribute to
a deterioration of cardiac function.
CRT has been generally accepted for drug-refractory
advanced heart failure with intraventricular conduction
delay and LV dyssynchrony. However, approximately 30%
of the patients who fulﬁll the CRT selection criteria do
not beneﬁt from CRT [1]. On the other hand, recent
reports indicate the presence of excellent responders to
CRT. Blanc et al. reported that 5 among the 29 patients
(17%) with DCM and CLBBB exhibited both complete nor-
malization of the LV function following CRT (EF from 19%
to 55%) and clinical improvement [2]. They proposed a
new concept of LBBB-induced or dyssynchrony-induced car-
diomyopathy with the normalization of the LV function
after the disappearance of LBBB. In addition, Castellant
et al. reported later that these cases were observed
in 11 patients (13%) among 84 patients of DCM with
LBBB and were called ‘‘hyperresponders’’, although no
patients with ischemic cardiomyopathy belonged to the
‘‘hyperresponders’’ group [3]. In Japan, Fujii and Takami
described two similar cases as ‘‘superresponders’’ [4]. In
the present case, the patient was diagnosed with DCM
and intermittent LBBB 9 years previously, on the evidence
of intact coronary arteries and poor LV performance with
an EF of 30%. LV dyssynchrony had already been pointed
out by echocardiography and left ventriculography. After
CRT, the LV performance was synchronized visually, which
resulted in normalization of the cardiac function. Therefore,
the present case is considered to be a ‘‘superresponder’’
to CRT.
MIBG, an analogue of norepinephrine, is a useful myocar-
dial tracer for detecting abnormalities in the myocardial
adrenergic nervous system in patients with heart failure [7].
A large number of previous studies have shown that medical
treatment of heart failure can improve cardiac sympathetic
nerve activity in patients with heart failure, as demon-
strated by MIBG scintigraphy. Moreover, several investigators
have reported that CRT improves cardiac sympathetic nerve
activity in CRT responders [8,9]. Nishioka et al. evaluated
the relationship between CRT response and MIBG scinti-
graphic parameters [8]. They concluded that the H/M ratio
was the only independent predictor of CRT response. They
suggested that the optimal H/M ratio (delayed phase) cut-
off point was 1.36, with 75% sensitivity and 71% speciﬁcity.
Although a delayed MIBG image was not acquired before CRT
in our case, the H/M ratio in the early phase was 1.88, which
was one of the reasons why we chose CRT. After CRT, the H/M
ratio increased from 1.88 to 2.32, and the washout rate indi-
cated 14.7%, which implied complete recovery of cardiac
sympathetic nerve activity.
In almost all reported cases of ‘‘superresponders’’, con-
ventional medical treatment, including diuretic, ACEI, ARB,
and/or beta-blocker, was maintained after CRT. Therefore,
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he inﬂuence of these drugs on the normalization of car-
iac function in ‘‘superresponders’’ cannot be excluded.
n other words, it remains unclear which contributes to
he normalized LV function, a single effect of CRT (correc-
ion of intraventricular conduction delay) or the combined
ffects of medical treatment and CRT. There have been
any previous reports that beta-blockers almost normalized
ardiac function in patients with DCM. In particular, accord-
ng to previous reports, carvedilol, a unique beta-blocker
ith alpha1-receptor blocking and antioxidant properties,
mproves cardiac sympathetic nerve activity and LV remod-
ling in patients with DCM [10—12]. Thus, we evaluated
he efﬁcacy of beta-blocker therapy in the normalization
f cardiac function following CRT. Under CRT, the potential
ffect of carvedilol on cardiac sympathetic nerve activity
as elucidated, using MIBG scintigraphy. One month after
he cessation of carvedilol administration, in spite of the
hort-term observation, the H/M ratio in the delayed phase
lightly decreased from 2.48 to 2.38 and the washout rate
lightly increased from 14.7% to 15.9%. These results sug-
ested that carvedilol therapy might have an additional
ffect on the improvement of cardiac sympathetic nerve
ctivity obtained after CRT. In addition, in the present case,
he cessation of carvedilol treatment led to mild aggrava-
ion of LV contractility and a mild increase in LV chamber
ize. It has been reported that carvedilol therapy stimu-
ates an increase in contractile function and a reduction of
ntraventricular dyssynchrony in DCM with narrow QRS com-
lex [13]. Therefore, these pharmacological effects might
ave partly contributed to the complete recovery of sym-
athetic nerve activity obtained after the combination of
RT and medical treatments. Moreover, the cessation of
arvedilol administration might attenuate the potential of
RT. In the present case, however, its attenuation was
onsidered to be quite limited in terms of inﬂuence on
ardiac function because of the minimal change in the
RS-width after the cessation of carvedilol administration.
n any case, we should note that cardiac function is not
ompletely restored in CRT ‘‘superresponders,’’ even after
aining resynchronization. However, a precise etiology of
he ‘‘latent’’ cardiac dysfunction disclosed by the cessa-
ion of beta-blocker treatment is unclear. Several factors
esponsible for the ‘‘remaining’’ myocardial damage in
‘superresponders’’ might be possible: preexisting heart dis-
ase and/or secondary myocardial degeneration triggered
y long-term dyssynchrony and/or incomplete synchrony.
hus, against the previous reports [2—4], it cannot sim-
ly be concluded that a ‘‘superresponder’’ to CRT would
e regarded as a patient with LBBB-induced cardiomy-
pathy without organic myocardial disease. In the future,
he relationship between the LV synchronicity and the
‘normalized’’ cardiac function in CRT ‘‘superresponders’’
s well as the existence of ‘‘pure’’ LBBB-induced car-
iomyopathy should be clariﬁed by prudent investigations.
oreover, a subset of ‘‘superresponders’’ should be properly
elected prior to CRT and the timely introduction of CRT is
lso essential.
In summary, we reported a case with DCM which exhib-
ted a dramatic reverse remodeling after CRT. In the
resent case, the combination of CRT and medical ther-
py exerted excellent effects on the long-term impaired
V function, leading to the complete recovery of cardiac
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[
[13] Takemoto T, Hozumi T, Sugioka K, Takagi Y, Matsumura
Y, Yoshiyama M, Abraham PT, Yoshikawa J. Beta-blocker62
ympathetic nerve activity. The present case warns that,
espite normalization of LV performance following CRT, sub-
ptimal medical treatment would lead to the aggravation of
ardiac function.
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